AI Article Synopsis
- Primary hepatic angiosarcoma (PHA) is a rare and aggressive liver cancer with a generally poor survival rate, as illustrated by a study involving 1500 patients where only two were diagnosed with it.
- Both studied patients who underwent a surgical procedure (hepatectomy) had limited postoperative survival times of 8 and 16 months.
- The findings suggest that complete surgical resection should be the primary treatment for PHA, with the possibility of improving survival through additional chemotherapy after surgery; palliative chemotherapy may also be considered for more advanced cases.
Article Abstract
Primary hepatic angiosarcoma (PHA) is a rare malignancy that carries a poor prognosis. Of 1500 patients who underwent hepatectomy for primary hepatic tumors between 1994 and 2013 at our center, two patients were pathologically diagnosed with PHA. Clinical characteristics, treatment modalities, and outcomes of the two patients were collected and analyzed. Both patients underwent hepatectomy and had a postoperative survival time of 8 and 16 mo, respectively. A search of PubMed yielded eight references reporting 35 cases of PHA published between 2004 and 2013. On the basis of the presented cases and review of the literature, we endorse complete surgical resection as the mainstay definitive treatment of PHA, with adjuvant postoperative chemotherapy potentially improving survival. Palliative chemotherapy is an option in advanced hepatic angiosarcoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438048 | PMC |
| http://dx.doi.org/10.3748/wjg.v21.i19.6088 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!